

Sepsis Treatment: Is There a Role For Vitamins ?

Jon Sevransky, MD, MHS, FCCM

Professor Of Medicine, Emory University School of Medicine

Director EUH MICU

Assistant Director for Medicine, Emory Center for Critical Care

Assistant Director for EUH, Emory Center for Critical Care

Associate Editor, Critical Care Medicine



EMORY
UNIVERSITY
SCHOOL OF
MEDICINE



Disclosures

Financial

- Grant Support Current
 - FDA/BARDA
 - Marcus Foundation
- Stipend from Critical Care Medicine for work as Associate Editor

Intellectual

- Medical Advisor to Project Hope (ARDS Advocacy Group)
- Member of Surviving Sepsis Guideline Committees (2004, 2008, 2012, 2016, 2020)



Talk Outline

- Review Treatment of Patients with Sepsis
- Review the Benefits and Limitations of Single Center vs Multicenter Clinical Trials
- Discuss the evidence supporting use of Vitamin C, Thiamine, and Steroids in Sepsis
- To Describe the Design of the VICTAS study (Vitamin C, Thiamine and Steroids in Sepsis)




Patient JM

- 66 year old with CML- extra lymphatic involvement S/P ABMT 60 days prior to admission
 - Admitted with GVHD with GI symptoms
 - Noted to have tachypnea to 30's B/P 90/55 pulse 108 T 38.5 wbc 1.2 lactate 4
 - Blood cultures oxidase positive gram negative rods
 - Started on ceftazidime
 - Transferred to ICU when required non-rebreather
- Infection
- Organ failure






Sepsis is a Medical Emergency

Concept Highlighted by Manny Rivers



Proper Orientation is Important

Sepsis Care Must Center Around the Patient



Sepsis is a Medical Emergency

- Treatment



- Similar conditions

Insight PRESENTS
TIME IS MUSCLE
STEMI STRATEGIES TO MATCH PATIENTS WITH THERAPY
A Live CME Breakfast Forum
Sunday, March 25, 2007 | 5:30am-7:00am
New Orleans Marriott
Blossard Ballroom, 2nd floor
Doors open for registration at 5:00am
Moderators
Jeffrey J. Probst, MD, FACC
Kip A. Condit, MD
Faculty
Paul A. Carlet, MD
David S. Gussner, MD, FACC
Register online now at www.InsightCME.org/stemi

**WITH A STROKE,
TIME LOST IS BRAIN LOST.**

Learn more at StrokeAssociation.org or 1-888-4-STROKE.

Ad Council

American Stroke Association.
A Division of American Heart Association



**Minute-by-Minute,
the Golden Hour
in Trauma Care**



EMOH
UNIVERSITY
SCHOOL OF
MEDICINE

Sepsis is...

- Life-threatening organ dysfunction caused by a dysregulated host response to infection¹
- **Common**: 0.9-3 million cases/yr^{2, 3}
- **Life-threatening**: 15-30% mortality²
- **Time-sensitive**: 8% mortality increase for every hour delay in initiation of antibiotics⁴
- **A major public health concern**: most expensive reason for US hospitalization^{5,6}



Sepsis is a Syndrome



- Disease
- Known Biomarker
- Diagnostic Test that enables identification
- Syndrome
- Constellation of signs and syndromes that lead to diagnosis



Sepsis Diagnosis- Not Always Simple



Partnering with Patients and Advocacy Groups




What is in the Sepsis Treatment Toolbox ?

- Early Recognition of Sepsis
- Early Antibiotics and Fluids
- Performance Improvement Projects



Timing of Antibiotics in Sepsis Induced Hypotension

- 2731 Patients with septic shock
- 44% Admissions From ED
 - Lung, Intra-abdominal and Urine most common sites of infection
- Mortality Rate 21% if Effective Antibiotics given within 1 hour
- Mortality Rate 58% if Effective Antibiotics given within 6 hours





Following Sepsis Guidelines Helps Patients

Not every patient gets treatment consistent with guidelines

Timeliness of Antibiotics associated with mortality

Timeliness of Fluids Not associated with mortality



Performance of Outcome Measurements: Did the Campaign Work?

Small Increase in Process Measures

Table 5. Impact of the Educational Program on Process-of-Care Measurement and Outcome Depending on Hospital Categorization According to Baseline Compliance With the Guidelines

Type of Measure	Preintervention Cohort	Postintervention Cohort	P Value
Category 1 hospitals (n = 20)			
No. of tasks completed, mean (SD) [95% CI]	3.25 (1.56) [3.0-3.4]	4.42 (1.97) [4.2-4.6]	<.001
Resuscitation bundle completed, No. (%) [95% CI]	1 (0.5) [0-1]	16 (4.7) [2-7]	.006
Management bundle completed, No. (%) [95% CI]	13 (6.4) [3-10]	36 (10.6) [7-14]	.10
Hospital mortality, No. (%) [95% CI]	98 (48.0) [41-55]	134 (39.3) [34-44]	.05
APACHE II, mean (SD) [95% CI]	20.6 (7.4) [19.6-21.6]	20.0 (7.3) [19.2-20.8]	.37
Category 2 hospitals (n = 19)			
No. of tasks completed, mean (SD) [95% CI]	4.65 (1.72) [4.46-4.85]	5.22 (1.98) [5.06-5.38]	<.001
Resuscitation bundle completed, No. (%) [95% CI]	11 (3.6) [2-6]	47 (7.8) [6-10]	.02
Management bundle completed, No. (%) [95% CI]	24 (7.9) [5-11]	67 (11.2) [9-14]	.13
Hospital mortality, No. (%) [95% CI]	135 (44.7) [39-50]	245 (40.9) [37-45]	.28
APACHE II, mean (SD) [95% CI]	20.7 (7.3) [19.8-21.6]	21.8 (8.1) [20.9-22.0]	.07
Category 3 hospitals (n = 20)			
No. of tasks completed, mean (SD) [95% CI]	5.90 (1.92) [5.70-6.11]	6.45 (2.00) [6.27-6.62]	<.001
Resuscitation bundle completed, No. (%) [95% CI]	33 (9.5) [6-13]	84 (16) [13-19]	.006
Management bundle completed, No. (%) [95% CI]	56 (16.1) [12-20]	127 (24.2) [21-28]	.004
Hospital mortality, No. (%) [95% CI]	143 (41.1) [36-46]	201 (38.3) [34-42]	.41
APACHE II, mean (SD) [95% CI]	21.5 (7.3) [20.7-22.3]	21.6 (7.7) [21.0-22.0]	.87

Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; CI, confidence interval.

Ferrer, R. et al. JAMA 2008;299:2294-2303.

Decreased Mortality Rate


Table 3. Performance of Outcome Measurements

	Preintervention Cohort (n = 854)	Postintervention Cohort (n = 1465)	P Value
Mortality, No. (%) [95% CI]			
Hospital	376 (44.0) [41-47]	580 (39.7) [37-42]	.04
28-d	311 (36.4) [33-40]	456 (31.1) [29-33]	.009
ICU	315 (36.9) [34-40]	474 (32.4) [30-35]	.03
Hospital stay, d ^a			
Mean (SD) [95% CI]	28.7 (23.4) [26.6-30.8]	30.7 (25.7) [29.0-32.4]	.16
Median (IQR)	20.9 (13.5-35.7)	22.8 (13.3-41.4)	.25
ICU stay, d ^a			
Mean (SD) [95% CI]	13.4 (16.0) [11.9-14.0]	13.6 (16.3) [12.5-14.7]	.87
Median (IQR)	7.6 (4.5-15.0)	7.7 (4.0-15.9)	.83

Abbreviations: CI, confidence interval; ICU, intensive care unit; IQR, interquartile range.
^aDeaths are excluded.



Multicenter Implementation of a Severe Sepsis and Septic Shock Treatment Bundle




- Increasing Compliance with Sepsis Bundle is Associated with Decreasing Patient Mortality
- Compliance with early bundles was associated with decreased need for later intervention
- Lung protective Mechanical Ventilation, inotropes, and steroids were interventions independently associated with mortality




Following Sepsis Guidelines Helps Patients

Not all sepsis patients get desired treatment



Time to Completion of 3 hour bundle associated with in hospital mortality




7.5 year Evaluation of a PI project on Sepsis (SSC)

Model	Risk factors ^a	OR (95% CI)	<i>p</i>
1. Continuous compliance, either resuscitation or management bundle, as a site-level variable and measured in last 2 quarters of site's SSC participation	For every additional quarter of site participation	0.96 (0.95–0.97)	< 0.001
	10% increase in resuscitation compliance	0.95 (0.94–0.97)	< 0.001
	10% increase in management compliance	0.97 (0.96–0.98)	< 0.001
2. Compliance as a patient-level variable and measuring whether patient's ICU visit was compliant with resuscitation or with management bundle	For every additional quarter of site participation	0.97 (0.96–0.98)	< 0.001
	Resuscitation compliance, yes vs. no	0.82 (0.76–0.88)	< 0.001
	Management compliance, yes vs. no	0.76 (0.71–0.81)	< 0.001

Resuscitation Compliance includes among other things 30 cc/kg /IVF



Serum Tumor Necrosis Factor Levels After Endotoxin Challenge



- Monoclonal antibodies to TNF given to animals challenged with endotoxin
 - reverse hemodynamic embarrassment
 - improve mortality




Clinical Sepsis Trials of Monoclonal Antibodies Directed Against TNF

Treatment Directed at Modulating Inflammation: Not Effective

Table 1. Clinical trials of anti-TNF MAb

Therapy (Company) [Reference]	Study design	Inclusion criteria	Control arm deaths/Total (%)	Treatment arm deaths/Total (%)
MAK 195F (Knoll) [12]	Open-label, phase II	Severe sepsis or septic shock (69%) ^a	12/29 (41%)	44/93 (47%)
MAK 195F (Knoll) [13]	Open-label, phase II	Severe sepsis or septic shock	6/12 (50%)	7/27 ^c (26%)
MAK 195F (Knoll) [3]	Double-blind, phase III	Sepsis and high IL-6 levels	125/221 (57%)	121/225 (54%)
CDP571 (Celltech) [14]	Open-label, phase II	Septic shock (100%) ^a	6/10 (60%)	20/32 ^c (63%)
CB006 (Celltech) ^b [15]	Open-label, phase II	Severe sepsis or septic shock	6/19 (32%)	27/61 ^c (44%)
BAYx1351 (Bayer/Miles) [16]	Double-blind, phase III	Severe sepsis or septic shock (49%) ^a	108/326 (33%)	196/645 ^c (30%)
BAYx1351 (Bayer/Miles) [17]	Double-blind, phase III	Severe sepsis or septic shock (80%) ^a	66/167 (40%)	144/386 ^c (37%)
BAYx1351 (Bayer/Miles) [18]	Double-blind, phase III	Septic shock (100%) ^a	398/930 (43%)	382/948 (40%)
cA2 (Centacor) [19]	Double-blind, phase II	Severe sepsis	11/28 (39%)	10/28 (36%)
Total			738/1742 (42%)	951/2445 (39%)

Odds Ratio for Treatment Effects of Mediator-Specific Anti-inflammatory Agents



Clinical Sepsis Trials That Did Not Show Beneficial Treatment Effect

Albumin Replacement in Patients

Goal-Directed Resuscitation for Patients

High versus Low Blood-Pressure Target

• • • • •

Early, Goal-Directed Therapy for Septic Shock

Lower versus Higher Hemoglobin Threshold for Transfusion

Hydrocortisone Therapy for Patients with Septic Shock



npr WABE 90.1 news arts & life music programs shop

 **shots** HEALTH NEWS FROM NPR

TREATMENTS

 2:28

[+ Queue](#)

Download

Embed

Transcript

Doctor Turns Up Possible Treatment For Deadly Sepsis

March 23, 2017 · 12:01 AM ET
Heard on Morning Edition

 RICHARD HARRIS 




Triple Therapy for Sepsis

Original Research

Hydrocortisone, Vitamin C and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study

Paul E. Marik, MD, FCCM, FCCP¹, Vikramjit Khangoora, MD¹, Racquel Rivera, Pharm D², Michael H. Hooper, M.D., MSc¹, John Catravas, PhD, FAHA, FCCP^{3,4}




EMORY
UNIVERSITY
SCHOOL OF
MEDICINE

CHEST (2017), doi: 10.1016/j.chest.2016.11.036

EMORY HEALTHCARE
EMORY CENTER FOR CRITICAL CARE


Biologic Rationale Vitamin C in Sepsis

- Antioxidant and enzyme co-factor
 - Activates Nrf2
 - Restores cellular antioxidants
 - Catecholamines
- Anti-inflammatory
 - ↓ NF-κB
- Necessary for tight junctions and microcirculatory flow




Thiamine

- Essential for aerobic metabolism:
 - Pyruvate dehydrogenase
 - Alpha ketoglutarate dehydrogenase



Thiamine and Vitamin C



Phase I Study of Vitamin C in Sepsis



- Patients- 26 Patients with severe sepsis (1.0) at VCU randomized 1:1:1
- Intervention Vitamin C 50 mg/kg/day in divided doses every 6 hours for 96 hours
- Or
- Vitamin C 200 mg/kg/day in divided doses every 6 hours for 96 hours

- Comparator Placebo

- Outcome measure- Sequential Organ Failure Assessment (SOFA scores) and Vitamin C Levels



Phase I Study of Vitamin C in Sepsis




Thiamine in Sepsis

- Patients- Adult patients with septic shock and elevated (> 3 mmol/L) lactate between 2010 and 2014 at 2 hospitals
- Intervention —Thiamine 200 mg twice daily for 7 days or until hospital discharge.
- Comparator- Placebo treated patients
- Outcome Lactate level 24 hours after first study dose



Thiamine in Sepsis




Triple Therapy for Sepsis

Original Research

Hydrocortisone, Vitamin C and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study

Paul E. Marik, MD, FCCM, FCCP¹, Vikramjit Khangoora, MD¹, Racquel Rivera, Pharm D², Michael H. Hooper, M.D., MSc¹, John Catravas, PhD, FAHA, FCCP^{3,4}



Rationale for Marik study

- Preliminary data
- Patients with sepsis have low serum levels of Vitamin C
- Patients with sepsis have low serum levels of thiamine
- Small studies have shown feasible to give supplemental Vitamin C and thiamine without obvious harm
- Potential synergistic effect of steroids and Vitamin C



Before-After Study

- Patients – 47 consecutive patients admitted to the ICU at Sentara Norfolk General Hospital with a primary diagnosis of severe sepsis or septic shock and a procalcitonin $\geq 2\text{ng/ml}$
- Intervention: intravenous vitamin C (1.5 gm q 6 hourly for 4 days or until ICU discharge), hydrocortisone (50 mg q 6 hourly for 7 days or until ICU discharge followed by a taper over 3 days), intravenous thiamine (200 mg q 12 hourly for 4 days or until ICU discharge).
- Comparator Patients with severe sepsis and septic shock with procalcitonin $\geq 2\text{ng/ml}$ treated during previous year without vitamin C or thiamine, but who could receive hydrocortisone per physicians orders
- Outcome Measure Hospital Survival



Additional analysis

- Propensity score:
 - Probability (0-1) of receiving treatment based on covariates
- Logistic regression for OR mortality
 1. Propensity score
 2. Propensity score + age

Covariates
Age
Weight
Gender
APACHE IV Score
Mechanical Ventilation
Vasopressors
WBC
Lactate
Procalcitonin
Serum Creatinine



Before-After Study

	Treated (n=47)	Control (n=47)
Age	58.3 ± 4.1	62.2 ± 14.3
Sex (male)	27 (57%)	23 (49%)
Comorbidities		
None	2 (4%)	1 (2%)
Diabetes	16 (34%)	20 (42%)
Hypertension	20 (43%)	25 (53%)
Heart Failure	15 (32%)	16 (34%)
Malignancy	5 (11%)	7 (15%)
COPD	8 (17%)	7 (15%)
Cirrhosis	6 (13%)	3 (6%)
CVA	8 (17%)	5 (11%)
CRF	7 (15%)	8 (17%)
Morbid Obesity	6 (13%)	8 (17%)
Immunocompromised	6 (13%)	4 (9%)
Drug addiction	5 (11%)	5 (11%)



Study Limitations

Single Center before and after study

Complex intervention

Steroids used in comparator arm

Little information about contemporaneous therapies (antibiotics, fluids etc)

Confirmation bias

Large effect size



Highly Polarizing Results

- A significant number of professionals immediately began prescribing this as a cure for sepsis
 - A significant number of professionals criticized the study very vociferously
 - Much of this discussion has been high-level intellectual discourse
 - Some of it has not been
-



Pneumococcal Bacteremia with Especial Reference to Bacteremic Pneumococcal Pneumonia

ROBERT AUSTRIAN, M.D., and JEROME GOLD, M.D.




FIGURE 6. Numbers in parentheses indicate size of each group of patients. Data for untreated and serum-treated patients (capsular Types I and II only) from Tilghman and Finland (1).

38% ARR

27% ARR



Single Vs Multicenter Trials

Phase II Single Center Trials

- Test potential novel therapies
- Show potential risks and benefits
- Easier to do/Cheaper
- May change practice at one site or with some physicians
- May have large treatment effects

Phase III Multicenter Trials

- Test Potential new therapies
- Show potential risks and benefits
- Harder to do/More expensive
- The gold standard for changing clinical practice
- Usually with smaller treatment effects



Why We Need a Clinical Trial

Vitamin C Is Not Ready for Prime Time in Sepsis but a Solution Is Close



To the Editor:

We read with interest the report by Marik et al¹ published in *CHEST* (June 2017). However, the study lacked blinding, randomization, concurrent control subjects, and case-control propensity matching; it also had a small sample size, thus substantially increasing the risk of false benefits due to confounding combined with selection and ascertainment biases. Many

resolution in an even shorter time.⁵ Considering this poor evidence on the safety and efficacy of vitamin C and how swiftly an adaptive RCT can be done, we believe that there is no ethical or scientific justification to use vitamin C outside of a clinical trial at this time.

Copyright © 2017 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

DOI: <http://dx.doi.org/10.1016/j.chest.2017.05.025>

Why We Need a Clinical Trial

Viewpoint 1

- To my knowledge, we have had zero patients treated at Vanderbilt. But Jon, you should emphasize this does not reflect any lack of enthusiasm for conducting a proper study, it reflects Vanderbilt's long-standing conservatism regarding "new" or "exciting" therapies, i.e., we believe it is proper to wait until there is sufficient high quality data to begin routinely using these treatments on everyday patients.
- Gordon Bernard MD

Viewpoint 2

- "It might help- that's why I used it"
- I'm on service right now and thought I'd relay an event that occurred simultaneous to the foundation presentation. We have a patient who was found down and seems to have acute on chronic liver disease with septic shock, AKI, DIC and ARDS. She was given thiamine because of the alcoholism and steroids because of refractory shock (vasopressin and 50+ mcg of norepinephrine). Because she was doing poorly despite a couple of days of maximal therapy the resident (all credit due) decided to add Vitamin C to the steroids and thiamine already being given. Within 24 hours her vasopressin was turned off and her norepinephrine was 2-5mcg. In full disclosure she also got NAC and albumin because of liver disease and possible HRS, but still!

What Kind of Evidence Should Change Practice ?

1- Single Physician and Single Patient

- Clinical Experience, Literature

2- Single Institution

- Clinician Agreement + Data Showing that Practice Change Works in that Institution

3- Most Patients

- > 1 RCT in a similar patient population

4- Treatment Guidelines

- >1 RCT in similar patient population + evaluation of quality of RCT + cost and downside of intervention



Phase III Multicenter Trials Change Practice



EMORY
UNIVERSITY
SCHOOL OF
MEDICINE

EMORY HEALTHCARE
EMORY CENTER FOR CRITICAL CARE

An Analogy For Multicenter vs. Single Center Trials

New York Knicks vs Cleveland Cavaliers Oct 30th 2017 NY 114 –Cleveland 95



- A multicenter trial is more likely to be reproduced than is a single center trial, just as a 7 or 82 game series is more likely to give the same result if repeated.



Trial Design- What Patient Population to Pick

Critically Ill Patients:

Mortality Endpoint

- More likely to immediately change practice
- Simpler Enrollment Criteria

- Fewer patients
- More sites required
- May take longer to complete

Very Sick but Not Yet Critical:

Rates & Speed of Improvement Endpoint

- Preventing progression to Critically Ill-
-May be appealing to Patients
- Applies to More Patients

- More complicated enrollment criteria
- Could be less compelling for immediate practice change

Consider nested study including both populations

Design Considerations

- Patients- which patient population are you studying
- Intervention- What are You Giving
- Comparator- What Treatment does the non-intervention arm get
- Outcome – What is the primary outcome measure



Victas PICO Questions

- Patients- Up to 2000 Adult patients with confirmed or suspected infection and evidence of respiratory or cardiovascular organ dysfunction (e.g. adult sepsis)
- Intervention Intravenous vitamin C (1.5 grams every 6 hours), thiamine (100 mg every 6 hours), and hydrocortisone (50 mg every 6 hours), will be administered in divided doses each day for 4 days or until ICU discharge.
- Comparator Placebo (unless clinical team desires to give steroids)
- Outcome- Vasopressor and Ventilator Free Days
 - 30 day mortality



Inclusion Criteria

- Patients > 18 with confirmed or suspected infection and evidence of respiratory or cardiovascular organ dysfunction
- Confirmed or suspected infection :ordering of blood cultures and administration of at least one antimicrobial agent
- Respiratory Dysfunction
 - Positive pressure ventilation (invasive or non invasive)
 - High Flow Nasal Cannula (≥ 45 L $\geq 45\%$)
- Cardiovascular Dysfunction
 - Vasopressors



Exclusion Criteria


Designed to limit exclusions
and make the study as pragmatic as possible

- Patients that are too ill from other causes in which the treatment is unlikely to fix the other problems (e.g., end stage cancer)
- Patients who refuse to participate
- Patients who are allergic to any of the treatments
- Patients with medical conditions that would make treatment higher risk (kidney stones, problems metabolizing calcium)
- Patients who are participating in another study



Sample Size

500 Patients- Simulation Data



If the Mortality Difference is 10% between groups, 500 patients would have 80% power to show it.




Estimates of Patients Needed

According To Differences in Mortality Between Treatment Groups

Treatment Effect	Patients Needed to Show Treatment Effect
32%	72 ← Marik Manuscript Treatment Effect
20%	250
10%	500
5%	2000



Interim Analysis Decision Tree ("bypass" Goldilocks)



Pr=Probability
 PFVD- vasopressor
 and ventilator free
 days (i.e alive and
 off vasopressors and
 ventilators)



Analytic Plan

- Final analysis will be done after all enrolled subjects are followed to Primary Endpoint
- For Vasopressor and Ventilator Free Days will use a Wilcoxon Rank Sum Test, using 1 sided alpha of 0.022 (to adjust to control Type I error rate at 0.025)
- In final analysis, patients who died are treated as though they had zero Ventilator and Vasopressor Free Days
- Managed with DCC, with assistance from Berry Consultants

VICTAS Trial Sites: 46 Enrolling Sites



VICTAS Team

Emory University:

Timothy G. Buchman, PhD, MD

Lawrence W. Busse, MD

Rie Calcaterra

Craig Coopersmith, MD

Neal Dickert, MD

Alex Hall, RN

Katherine L. Heilpern MD

Greg S. Martin, MD, MSc

Caroline Rudolph, MBA

Jonathan Sevransky, MD, MHS (PI)

David W. Wright, MD (Co-PI)

Johns Hopkins University:

Roy G. Brower, MD

David N. Hager, MD, PhD

Gabor David Kelen, MD

Richard E. Rothman, MD, PhD (Co-PI)

Lauren Sauer, MS

Vanderbilt University:

Gordon R. Bernard, MD

E. Wesley Ely, MD

Virginia Commonwealth University:

Christine DeWilde, RN, MSN

Alpha A. Fowler, III, MD

Ramesh Natarajan, PhD

Anna Priday, MS, CCRA

Eastern Virginia Medical School:

Michael H. Hooper, MD, MSc


Jefferson University

David F. Gaieski, MD

National Institutes of Health (NIH):

Mark A. Levine, MD

500 Patient Milestones



- Thank you

- Jsevran@emory.edu